| An SI Board Since March 1997 |
| Posts |
SubjectMarks |
Bans |
| 10 |
0 |
0
|
|
There's a huge movement toward the search of rapid diagnosis of acute mycardial infarction (heart attacks). Rapid diagnosis with the use of thrombolytics (which are also relatively new to medical practice) lead to increased survival and decreased morbidity. DIAGF (Spectral Diagnostics) is one such company that specializes in rapid detection of heart attacks through their troponin I assay.
--------
Spectral Diagnostics Inc. Receives Patent 5,604,105 Extending Its Proprietary Approach To Cardiac Diagnostics
Spectral to License Technology to Non-competitors
TORONTO, Feb. 28 /CNW-PRN/ - Spectral Diagnostics Inc. (TSE-SDI; NASDAQ- DIAGF), developers of the Cardiac STATus(TM) line of rapid format cardiac diagnostic test kits, reported today that the U.S. Patent and Trademark Office has issued to Spectral U.S. Patent 5,604,105, effective February 18, 1997. The patent, issued in the United States, materially extends protection of Spectral's multiple analyte approach to cardiac diagnostics in determining the origins of chest pain, and complements Spectral's patent applications which already exists in other countries.
In making the announcement Douglas C. Ball, Chairman and CEO said, ``This patent resulted from our determination to extend Spectral's founding invention - the measurement of multiple cardiac markers - to include all commercially available methods of measurement. We're aware that other companies have or intend to incorporate what is now Spectral's patented approach to cardiac diagnostics.'' Continuing he said, ``We have an excellent business opportunity to license this technology to numerous companies not directly competitive with Spectral's unique point of care cardiac diagnostics panel test kits. Discussions are already underway with potential licensees in the United States and abroad.''
The original United States Patent, issued in 1994, protected Spectral's multiple analyte approach utilizing specific analytes measured in a panel test platform. The new patent extends protection to Spectral's pioneering concepts of detecting multiple analytes drawn from an extensive list of combinations of cardiac analytes defined by their properties and independent of platform. The procedures described in this patent rely essentially on antigen-antibody reactions utilizing classic sandwich and competitive techniques. Unlike Spectral's previous patent, this patent greatly expands the application of measurement techniques beyond limits of dry chemistry membranes on defined carriers to automated systems based on various biosensor methods.
Covered in the patent are numerous combinations of cardiac markers that include Troponin I, Troponin T, myoglobin, CK-MB, glycogen phosphorylase, fatty acid binding proteins, carbonic anhydrase etc.
Located in Canada, the United States and Europe, Spectral's scientists, sales and marketing organizations and other professionals are focused on the development, manufacturing and commercialization of its Cardiac STATus(TM) line of diagnostic panel tests including the CK-MB/Myoglobin Panel Test, the Troponin I Panel Test and the patented Cardiac Panel(TM). Spectral's common shares are listed on The Toronto Stock Exchange (symbol SDI) and the NASDAQ - NMS - Exchange (symbol DIAGF).
|
|
|
